Skip to content
August 18, 2022

Equity.Guru

Investment information for the new generation

Bucillamine

The COVID-19 pandemic and variant friends are almost securely in our rear-view for another year and soon the beaches will be full of people and the papers will be…
Latest News Revive Therapeutics Ltd. (RVV.C) has provided an update for the Company’s U.S. Food and Drug Administration (FDA) Phase 3 clinical trial to evaluate the safety and efficacy…
We’re closing in on three years now and it’s becoming hard to believe there was a market before COVID-19. We can barely remember it. Cannabis was a thing briefly,…
Revive Therapeutics (RVV.C) has provided an update on the Company’s US Food and Drug Administration (FDA) Phase 3 clinical trial to evaluate the safety and efficacy of bucillamine in…
Revive Therapeutics (RVV.C) is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. RVV holds 13 patents (issued and…
Revive Therapeutics (RVV.C) entered into a memorandum of understanding with Indian pharmaceutical company, Supriya Lifescience, which includes manufacturing, clinical registration and commercialization for Bucillamine, according to a press release….
Revive Therapeutics (RVV.C) signed a research agreement with the University of California, San Francisco (UCSF) to explore Bucillamine as a potential treatment for severe cases of COVID-19 today, according…
“Psilocybin offers a potential solution to manage moderate to severe cases of TBI,” stated RVV, “Psilocybin has the potential with its neuroreparative effect to improve loss of cognitive function…
Revive Therapeutics (RVV.C) provided an update on their FDA Phase III clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate Covid-19.  …
Revive Therapeutics (RVV.C) provided an update on their Phase 3 clinical trial for bucillamine for COVID-19 today. Primarily, the update’s about funding and more specifically their recent $23 million…